Kollins et al., (2011) evaluated the efficacy and safety of
lisdexamfetamine in participants with attention deficit hyperactivity
disorder and a history of depression and/or substance use
disorder, with histories of these comorbidities was recorded from
medical history forms completed by the study clinicians.